Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Status:
Withdrawn
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This study will be performed as a local multicenter, randomized, phase III clinical study. It
will compare the adjuvant chemotherapy in Stage IB-IIIA NSCLC with common EGFR mutation (Exon
19 deletion or L858R) who underwent total resection and the Erlotinib-Intercalation adjuvant
chemotherapy with the chemotherapy alone. The patients will be randomly assigned to the
Intercalation combination chemotherapy regimen and the chemotherapy alone regimen at the
ratio of 1:1. The treatment regimen of each arm is as follows.